The Immunogenicity of Intradermal Influenza Vaccination in Hemodialysis Patients
The Immunogenicity of Intradermal Influenza Vaccination in Hemodialysis Patients
The purpose of this study is to determine whether half-dose intradermal influenza vaccine is
 as immunogenic as standard dose intramuscular vaccine in hemodialysis patients.
Hemodialysis patients are at high risk of influenza infection due to suppress immune
 status.It is recommended to immunize them against influenza annually.in intradermal
 vaccination antigens directly present to the large numbers of antigen-presenting cells in the
 skin and it may cause greater immunogenicity than in the intramuscular method. Reduced-dose
 intradermal influenza vaccine is immunogenic in healthy adult, patients with solid cancer and
 three groups of immunocompromized patients including Rheumatologic patients treated with
 anti-TNF, HIV-infected and stem cell transplanted patients.

 In this study we compare the efficacy of influenza vaccines in half dose intradermal and
 standard intramuscular methods among hemodialysis patients.
Inclusion Criteria:

 -  Patients under chronic hemodialysis

 Exclusion Criteria:

 -  history of flu infection in last month

 -  history of flu vaccination in 2009

 -  hospitalization in last month

 -  taking immune suppressants drugs

 -  hemodialysis less than twice weekly